Balaxi Pharma Q4 PAT declines to Rs8.4cr; Revenue drops to Rs53cr due to Chinese holidays; Stock rises 4.5%

The company said that for Q4FY21, the Pharmaceutical business segment contributed 58% of the consolidated revenues and 72% of the total gross profit.

from India Infoline News Service https://ift.tt/34ff8Ru